A randomized, open-label, phase II trial comparing neoadjuvant trastuzumab (T), pertuzumab (P) and endocrine therapy (ET)+/- PI3K inhibitor inavolisib in patients with HER2+/HR+, PIK3CA -mutant (mt) early breast cancer (BC)- GeparPiPPa.

Authors :: Reinisch, M.
Denkert, C.
Schneeweiß, A.
Seiler, S.
Weide, R.
Link, T.
Bjelic-Radisic, V.
Untch, M.
Rhiem, K.
Solbach, C.
Blohmer, J.-U.
Nekljudova, V.
Holtschmidt, J.
Loi, S.
Sibylle, S.
Source :: Senologie; Jun2024, Vol. 21 Issue 2, pe32-e32, 1p
Publication Year :: 2024

Full Text Access

Tools